论文部分内容阅读
目的:比较喜炎平注射液与利巴韦林治疗小儿上呼吸道感染的临床疗效。方法:将250例确诊为上呼吸道感染的患儿随机均分为两组,治疗组125例静脉给予喜炎平注射液5mg·kg-1·d-1治疗,对照组125例静脉给予利巴韦林10mg·kg-1·d-1治疗,对比两组治疗效果。结果:治疗组总有效率为97.6%,对照组为90.4%(P<0.05);治疗组热退时间、止咳时间、咽充血消退时间分别为(2.50±1.20)、(3.50±1.60)、(4.69±0.80)天,对照组分别为(4.30±1.30)、(5.40±2.10)、(4.73±0.85)天,差异有统计学意义。结论:喜炎平注射液治疗小儿上呼吸道感染更安全有效,值得临床推广应用。
Objective: To compare the clinical effects of Xiyanping injection and ribavirin in treating pediatric upper respiratory tract infection. Methods: A total of 250 children diagnosed as upper respiratory tract infection were randomly divided into two groups. 125 cases in the treatment group were treated with Xiyanping injection 5 mg · kg -1 · d -1, while in the control group 125 cases were given intravenously Waring 10mg · kg-1 · d-1 treatment, the two groups were compared. Results: The total effective rate was 97.6% in treatment group and 90.4% in control group (2.50 ± 1.20, 3.50 ± 1.60, 4.69 ± 0.80) days, the control group were (4.30 ± 1.30), (5.40 ± 2.10), (4.73 ± 0.85) days, the difference was statistically significant. Conclusion: Xiyanping injection in children with upper respiratory tract infection is safer and more effective, worthy of clinical application.